

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6129877

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	INTELLECTUAL PROPERTY SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date
G1 THERAPEUTICS, INC.	05/29/2020

RECEIVING PARTY DATA

Name:	HERCULES CAPITAL, INC., AS COLLATERAL AGENT
Street Address:	400 HAMILTON AVENUE, SUITE 310
City:	PALO ALTO
State/Country:	CALIFORNIA
Postal Code:	94301

PROPERTY NUMBERS Total: 102

Property Type	Number
Patent Number:	9487530
Patent Number:	10085992
Patent Number:	9464092
Patent Number:	9931345
Patent Number:	10189849
Patent Number:	10189850
Patent Number:	10189851
Patent Number:	8691830
Patent Number:	8829012
Patent Number:	8822683
Patent Number:	9102682
Patent Number:	9499564
Patent Number:	9481691
Patent Number:	9957276
Patent Number:	8598186
Patent Number:	8598197
Patent Number:	9527857
Patent Number:	10076523
Patent Number:	10434104
Patent Number:	9260442

PATENT

Property Type	Number
Patent Number:	9745316
Patent Number:	9856268
Patent Number:	10464940
Patent Number:	9717735
Patent Number:	10376519
Patent Number:	10413547
Patent Number:	10231969
Patent Number:	10618905
Patent Number:	10118910
Patent Number:	10377735
Patent Number:	10208011
Patent Number:	10633362
Patent Number:	10202392
Patent Number:	9808461
Application Number:	61800214
Application Number:	16268317
Application Number:	61798772
Application Number:	16112360
Application Number:	15943278
Application Number:	61406498
Application Number:	16226430
Application Number:	61861374
Application Number:	61911354
Application Number:	61949786
Application Number:	16178419
Application Number:	61949795
Application Number:	16228308
Application Number:	61617657
Application Number:	61980918
Application Number:	62050035
Application Number:	16142574
Application Number:	16572418
Application Number:	62050043
Application Number:	16254364
Application Number:	62357630
Application Number:	16230396
Application Number:	62357797
Application Number:	16230381

Property Type	Number
Application Number:	62357516
Application Number:	16230388
Application Number:	62357818
Application Number:	16847426
Application Number:	62526937
Application Number:	16721631
Application Number:	62264971
Application Number:	62322878
Application Number:	16537079
Application Number:	62430302
Application Number:	62479605
Application Number:	16432244
Application Number:	16424240
Application Number:	62411988
Application Number:	16393258
Application Number:	62443588
Application Number:	16460502
Application Number:	62462094
Application Number:	16547342
Application Number:	62457643
Application Number:	62460358
Application Number:	62614279
Application Number:	16824290
Application Number:	16227456
Application Number:	62613727
Application Number:	62614952
Application Number:	62679575
Application Number:	62788017
Application Number:	62655135
Application Number:	62657373
Application Number:	62788024
Application Number:	62810802
Application Number:	62672474
Application Number:	62827696
Application Number:	62722675
Application Number:	62764757
Application Number:	62827703
Application Number:	62870351

Property Type	Number
Application Number:	62758388
Application Number:	62827692
Application Number:	62870357
Application Number:	62863153
Application Number:	62907375
Application Number:	62913055

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7145401235

Email: IPDOCKET@LW.COM, KRISTIN.AZCONA@LW.COM

Correspondent Name: LATHAM & WATKINS LLP

Address Line 1: 650 TOWN CENTER DRIVE, 20TH FLOOR

Address Line 4: COSTA MESA, CALIFORNIA 92626

ATTORNEY DOCKET NUMBER:	054809-0065
NAME OF SUBMITTER:	KRISTIN J AZCONA
SIGNATURE:	/KJA/
DATE SIGNED:	05/29/2020

Total Attachments: 37

source=Hercules - G1 Therapeutics - Intellectual Property Security Agreement
EXECUTED(116069777.5)#page1.tif

source=Hercules - G1 Therapeutics - Intellectual Property Security Agreement
EXECUTED(116069777.5)#page2.tif

source=Hercules - G1 Therapeutics - Intellectual Property Security Agreement
EXECUTED(116069777.5)#page3.tif

source=Hercules - G1 Therapeutics - Intellectual Property Security Agreement
EXECUTED(116069777.5)#page4.tif

source=Hercules - G1 Therapeutics - Intellectual Property Security Agreement
EXECUTED(116069777.5)#page5.tif

source=Hercules - G1 Therapeutics - Intellectual Property Security Agreement
EXECUTED(116069777.5)#page6.tif

source=Hercules - G1 Therapeutics - Intellectual Property Security Agreement
EXECUTED(116069777.5)#page7.tif

source=Hercules - G1 Therapeutics - Intellectual Property Security Agreement
EXECUTED(116069777.5)#page8.tif

source=Hercules - G1 Therapeutics - Intellectual Property Security Agreement
EXECUTED(116069777.5)#page9.tif

source=Hercules - G1 Therapeutics - Intellectual Property Security Agreement
EXECUTED(116069777.5)#page10.tif

source=Hercules - G1 Therapeutics - Intellectual Property Security Agreement
EXECUTED(116069777.5)#page11.tif

source=Hercules - G1 Therapeutics - Intellectual Property Security Agreement
EXECUTED(116069777.5)#page12.tif

[illegible]

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT ("Agreement") dated as of May 29, 2020, is made by G1 THERAPEUTICS, INC., a Delaware corporation, and each domestic Subsidiary signatory hereto (individually and collectively, the "Grantor"), in favor of HERCULES CAPITAL, INC., a Maryland corporation ("Agent") in its capacity as collateral agent for the Lenders (as defined below).

RECITALS

A. Grantor has entered into a Loan and Security Agreement with certain financial institutions party thereto (the "Lenders") and Agent, in its capacity as administrative agent and collateral agent for itself and the Lenders, dated as of the date hereof (as amended, restated, or otherwise modified from time to time, the "Loan Agreement"). All capitalized terms used but not defined herein shall have the respective meanings given to them in the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. To secure its obligations under the Loan Agreement, Grantor grants and pledges to Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions, re-examination certificates, utility models, and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(f) All mask works or similar rights available now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the "Mask Works");

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing, the Intellectual Property Collateral does not include any "intent to use" trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, provided, that upon submission and acceptance by the United States Patent and Trademark Office of an amendment to allege use of an intent-to-use trademark application pursuant to 15 U.S.C. Section 1060(a) (or any successor provision) such intent-to-use application shall constitute Collateral.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Agent.

Grantor hereby authorizes Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

3. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Agent with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

4. Execution in Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

5. Successors and Assigns. The provisions of this Agreement shall inure to the benefit of the parties hereto and their respective successors and assigns. Grantor shall not assign its obligations under this Agreement without Agent's express prior written consent, and any such attempted assignment shall be void and of no effect. Agent may assign, transfer, or endorse its rights hereunder pursuant to the terms of the Loan Agreement without prior notice to Grantor, and all of such rights shall inure to the benefit of Agent's successors and assigns.

6. Governing Law. This Agreement has been negotiated and delivered to Agent in the State of California, and shall have been accepted by Agent in the State of California. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

7. Electronic Execution of Certain Other Documents. The words "execution," "execute," "signed," "signature," and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments,


waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

[Signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

G1 THERAPEUTICS, INC., a Delaware corporation


A handwritten signature in black ink, appearing to read "Jennifer Moses", is written over a horizontal line.

By: Jennifer Moses

Title: Chief Financial Officer

AGENT:

HERCULES CAPITAL, INC., a Maryland
corporation

A handwritten signature in black ink, appearing to be 'J. Choe', written over a horizontal line.

By: Jennifer Choe

Title: Associate General Counsel

[Signature Page to Intellectual Property Security Agreement]

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

[To be attached]

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-002P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation	61/800,214	3/15/2013			
12024-002US5	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	TRANSIENT PROTECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AGAINST IONIZING RADIATION	16/268,317	2/5/2019	US 2019-0167691 A1	6/6/2019	
12024-002WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation	PCT/US14/29073	3/14/2014	WO 2014/144596	9/18/2014	
12024-003AL1	AL - (Albania)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003AT1	AT - (Austria)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	2014762438	3/14/2014	EP2968290	1/20/2016	1183142
12024-003BA1	BA - (Bosnia-Herzegovina)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003BE1	BE - (Belgium)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003BG1	BG - (Bulgaria)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003CA1	CA - (Canada)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	2,906,156	3/14/2014			
12024-003CH1	CH - (Switzerland)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003CN1	CN - (China P.R.)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	201480027281.8	3/14/2014	CN 105473140 A	4/6/2016	ZL 2014800272818
12024-003CN2	CN - (China P.R.)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	201810253672.1	3/14/2014	CN 108283644 A	7/17/2018	
12024-003CY1	CY - (Cyprus)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003CZ1	CZ - (Czech Republic)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	2014-762438	3/14/2014	EP2968290	1/20/2016	2968290
12024-003DE1	DE - (Germany)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	60 2014 054 239.5
12024-003DK1	DK - (Denmark)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
		INC. - (GTI)							
12024-003EE1	EE - (Estonia)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003EP1	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003EP2	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	19198057.2	9/18/2019			
12024-003ES1	ES - (Spain)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003FI1	FI - (Finland)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003FR1	FR - (France)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003GB1	GB - (Great Britain)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003GR1	GR - (Greece)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003HK1	HK - (Hong Kong)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	16111632.3	3/14/2014	1223293A	7/28/2017	1223293B
12024-003HK2	HK - (Hong Kong)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	19100793.8	1/17/2019	1258477A	11/15/2019	
12024-003HR1	HR - (Croatia)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003HU1	HU - (Hungary)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003IE1	IE - (Ireland)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003IS1	IS - (Iceland)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-003ITI	IT - (Italy)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	502019000102951	3/14/2014	EP2968290	1/20/2016	2968290
12024-003JP1	JP - (Japan)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	2016-502870	3/14/2014	2016-513737	5/16/2016	6430483
12024-003JP2	JP - (Japan)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	2018-204234	3/14/2014			
12024-003LT1	LT - (Lithuania)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003LU1	LU - (Luxembourg)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003LV1	LV - (Latvia)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003MC1	MC - (Monaco)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003ME1	ME - (Montenegro)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003MK1	MK - (Macedonia)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	2019/1011	3/14/2014	EP2968290	1/20/2016	2968290
12024-003MO1	MO - (Macao)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	J/003178	3/14/2014			J/003178
12024-003MT1	MT - (Malta)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003NL1	NL - (Netherlands)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003NO1	NO - (Norway)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003PT1	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Inactive - (I)	Transient Protection of Normal Cells During Chemotherapy	61/798,772	3/15/2013			
12024-003PL1	PL - (Poland)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003PT1	PT - (Portugal)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-003R01	RO - (Romania)	Therapeutics, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003RS1	RS - (Serbia-Montenegro)	Therapeutics, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	2019/1537	3/14/2014	EP2968290	1/20/2016	2968290
12024-003SE1	SE - (Sweden)	Therapeutics, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003SK1	SK - (Slovak Republic)	Therapeutics, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003SI1	SI - (Slovenia)	Therapeutics, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003SM1	SM - (San Marino)	Therapeutics, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2968290
12024-003TR1	TR - (Turkey)	Therapeutics, INC. - (GTT)	Granted - (G)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	14762438.1	3/14/2014	EP2968290	1/20/2016	2019/19092
12024-003US1	US - (United States)	Therapeutics, INC. - (GTT)	Granted - (G)	Transient Protection of Normal Cells During Chemotherapy	14/212,430	3/14/2014	US 2014-0275066 A1	9/18/2014	9487530
12024-003US1CON1	US - (United States)	Therapeutics, INC. - (GTT)	Granted - (G)	Transient Protection of Normal Cells During Chemotherapy	15/342,990	11/3/2016	US-2017-0065597-A1	3/9/2017	10085992
12024-003US1CON2	US - (United States)	Therapeutics, INC. - (GTT)	Filed - (F)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	16/112,360	8/24/2018	US 2018-0360840 A1	12/20/2018	
12024-003US2	US - (United States)	Therapeutics, INC. - (GTT)	Granted - (G)	Transient Protection of Normal Cells During Chemotherapy	14/212,911	3/14/2014	US 2014-0275067 A1	9/18/2014	9464092
12024-003US2CON1	US - (United States)	Therapeutics, INC. - (GTT)	Granted - (G)	Transient Protection of Normal Cells During Chemotherapy	15/288,878	10/7/2016	US-2017-0037051-A1	2/9/2017	9,931,345
12024-003US2CON2	US - (United States)	Therapeutics, INC. - (GTT)	Filed - (F)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	15/943,278	4/2/2018	US 2018-0221378 A1	8/9/2018	
12024-003WO1	WO - (Patent Cooperation Treaty)	Therapeutics, INC. - (GTT)	Filed - (F)	TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY	PCT/US14/28685	3/14/2014	WO 2014/144326	9/18/2014	
12024-008AL1	AL - (Albania)	Therapeutics, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008AT1	AT - (Austria)	Therapeutics, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	E-807600

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-008AU1	AU - (Australia)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	2011323739	10/25/2011	2011323739	5/2/2013	2011323739
12024-008AU2	AU - (Australia)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK Inhibitors	2016204879	10/25/2011	2016204879	7/28/2016	2016204879
12024-008BE1	BE - (Belgium)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008BG1	BG - (Bulgaria)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008BR1	BR - (Brazil)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	CDK INHIBITORS	BR112013010018-4	10/25/2011	BR112013010018-4	8/2/2016	
12024-008CA1	CA - (Canada)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	2,815,084	10/25/2011	2,815,084	5/10/2012	2,815,084
12024-008CA2	CA - (Canada)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	2,961,937	10/25/2011	2,961,937	5/10/2012	2,961,937
12024-008CH1	CH - (Switzerland)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008CN1	CN - (China P.R.)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	201180062297.9	10/25/2011	CN103429243A	12/4/2013	ZL 20111800622979
12024-008CN2	CN - (China P.R.)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK Inhibitors	201410184792.2	10/25/2011	CN 103936745 A	7/23/2014	ZL 2014101847922
12024-008CN4	CN - (China P.R.)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	201610323241.9	10/25/2011	CN106008533A	10/12/2016	ZL 2016103232419
12024-008CY1	CY - (Cyprus)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008CZ1	CZ - (Czech Republic)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	CZ/EP2632467 T3
12024-008DE1	DE - (Germany)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	60 2011 027 640.9
12024-008DE2	DE - (Germany)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	16168485.7	10/25/2011	3118203	1/18/2017	60 2011 053 342.8
12024-008DK1	DK - (Denmark)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-008EE1	EE - (Estonia)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	E012491
12024-008EP1	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008EP2	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	CDK INHIBITORS	15170738.7	10/25/2011	EP2955183	12/16/2015	
12024-008EP3	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	16168485.7	10/25/2011	3118203	1/18/2017	3118203
12024-008EP4	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	18167945.7	10/25/2011	3381920	10/3/2018	3381920
12024-008EP5	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	CDK INHIBITORS	19164126.5	3/20/2019	3567042	11/13/2019	
12024-008ES1	ES - (Spain)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008FI1	FI - (Finland)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008FR1	FR - (France)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008GB1	GB - (Great Britain)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008GB2	GB - (Great Britain)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	16168485.7	10/25/2011	3118203	1/18/2017	3118203
12024-008GB4	GB - (Great Britain)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	18167945.7	10/25/2011	3381920	10/3/2018	3381920
12024-008GR1	GR - (Greece)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008HK2	HK - (Hong Kong)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	14108524.2	10/25/2011	HK1195067	10/31/2014	1195067B

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-008HK4	HK - (Hong Kong)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	CDK INHIBITORS	18113421.2	10/18/2018	1254345	7/19/2019	
12024-008HK5	HK - (Hong Kong)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	CDK INHIBITORS	42020004918.7	3/26/2020			
12024-008HR1	HR - (Croatia)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008HU1	HU - (Hungary)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008IE1	IE - (Ireland)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008IL2	IL - (Israel)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	Derivatives of 6-oxo-pyrazinopyrrolopyrimidines	237581	10/25/2011	237581	11/29/2018	
12024-008IL3	IL - (Israel)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	CDK Inhibitors	237582	10/25/2011	237582	4/30/2015	
12024-008IL4	IL - (Israel)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	TRICYCLIC LACTAM COMPOUNDS AND DERIVATIVES USEFUL AS CDK INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF	252108	10/25/2011		7/31/2017	
12024-008IL5	IL - (Israel)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	CDK INHIBITORS	271977	10/25/2011			
12024-008IN1	IN - (India)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	PYRROLOPYRIMIDINE FUSED PIPERAZINONE COMPOUNDS AS CDK INHIBITORS	3795/CHENP/2013	10/25/2011	3795/CHENP/2013	8/29/2014	307331
12024-008IS1	IS - (Iceland)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008IT1	IT - (Italy)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	502016000090111	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008JP1	JP - (Japan)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	2013-535153	10/25/2011	5923509	5/24/2016	5923509
12024-008JP2	JP - (Japan)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	2016-082206	10/25/2011	2016-183161	10/20/2016	6157680
12024-008JP3	JP - (Japan)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	2017-110115	10/25/2011	2017-186357	10/12/2017	6389926

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-008KR1	KR - (Republic of Korea)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	10-2013-7013388	10/25/2011	10-2014-0003427	1/9/2014	10-1929593
12024-008KR2	KR - (Republic of Korea)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	10-2018-7035510	10/25/2011	1020180135086	12/19/2018	10-2051881
12024-008KR3	KR - (Republic of Korea)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	CDK INHIBITORS	10-2019-7035200	10/25/2011			
12024-008LT1	LT - (Lithuania)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008LU1	LU - (Luxembourg)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008LV1	LV - (Latvia)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008MC1	MC - (Monaco)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008MK1	MK - (Macedonia)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008MO1	MO - (Macao)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	J/002324	10/25/2011			J/002324
12024-008MT1	MT - (Malta)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008MX1	MX - (Mexico)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	MX/a/2013/004681	10/25/2011	MX2013004681	10/17/2013	338327
12024-008MX2	MX - (Mexico)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	CDK INHIBITORS	MX/a/2016/004581	10/25/2011			
12024-008MX3	MX - (Mexico)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	CDK INHIBITORS	MX/a/2019/010602	9/5/2019	MX/a/2019/010602	11/11/2019	
12024-008NL1	NL - (Netherlands)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008NO1	NO - (Norway)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	Cyclin-Dependent Kinase Inhibitors	61/406,498	10/25/2010			

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-008PL1	PL - (Poland)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008PT1	PT - (Portugal)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008RO1	RO - (Romania)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008RS1	RS - (Serbia-Montenegro)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008RU1	RU - (Russian Federation)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	2013123790	10/25/2011	2013123790	12/10/2014	2621674
12024-008RU2	RU - (Russian Federation)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	CDK INHIBITORS	2017117633	5/27/2013			
12024-008SE1	SE - (Sweden)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008SG1	SG - (Singapore)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	201303155-4	10/25/2011	SG 189525 A1	5/31/2013	189525
12024-008SG2	SG - (Singapore)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	10201508715Y	10/25/2011	10201508715Y	11/27/2015	10201508715Y
12024-008SI1	SI - (Slovenia)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008SK1	SK - (Slovak Republic)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	E 21964
12024-008SM1	SM - (San Marino)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	11838545.9	10/25/2011	EP2632467	9/4/2013	SM-T-201600311
12024-008TR1	TR - (Turkey)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	201613256	10/25/2011	EP2632467	9/4/2013	EP2632467
12024-008US10	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	15/918.834	3/12/2018	US 2018-0201617 A1	7/19/2018	10189849
12024-008US11	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	15/918.852	3/12/2018	US 2018-0201618 A1	7/19/2018	10189850
12024-008US12	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	15/918.877	3/12/2018	US 2018-0201619 A1	7/19/2018	10189851

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-008US13	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	CDK INHIBITORS	16/226,430	12/19/2018	US 2019-0119292 A1	4/25/2019	
12024-008US3	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	13/869,594	10/25/2011	US 2013-0237534 A1	9/12/2013	8,691,830
12024-008US4	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	14/162,637	1/23/2014	US 2014-0142306 A1	5/22/2014	8,829,012
12024-008US5	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	14/162,649	1/23/2014	US 2014-0142299 A1	5/22/2014	8,822,683
12024-008US6	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK Inhibitors	14/452,296	8/5/2014	US 2015-0031880 A1	1/29/2015	9,102,682
12024-008US7	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK Inhibitors	14/712,582	5/14/2015	US 2015-0246925 A1	9/3/2015	9,499,564
12024-008US8	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK Inhibitors	14/712,630	5/14/2015	US 2015-0246926 A1	9/3/2015	9481691
12024-008US9	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK Inhibitors	15/348,770	11/10/2016	US-2017-0057971-A1	3/2/2017	9,957,276
12024-008WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTT)	Inactive - (I)	CDK INHIBITORS	PCT/US2011/057749	10/25/2011	WO/2012/061156	5/10/2012	
12024-008WO1AU3	AU - (Australia)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	CDK INHIBITORS	2018202991	10/25/2011	2018202991	5/17/2018	
12024-008WO1BRI-DIV	BR - (Brazil)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	KINASE INHIBITOR COMPOUNDS DEPENDING ON CYCLINE AND PHARMACEUTICAL COMPOSITION	BR122020005118-3	3/13/2020			
12024-008WO1US1	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	13/869,520	10/25/2011	US 2013-0237544 A1	9/12/2013	8,598,186
12024-008WO1US2	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	CDK INHIBITORS	13/869,576	10/25/2011	US 2013-0237533 A1	9/12/2013	8,598,197
12024-010CA1	CA - (Canada)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION	2,906,166	3/14/2014	2,906,166	9/18/2014	
12024-010CN1	CN - (China P.R.)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION	201480027269,7	3/14/2014	CN 105407889 A	3/16/2016	ZL 2014800272697
12024-010CN2	CN - (China P.R.)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION	201810443050,5	3/14/2014	108434149	8/24/2018	

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-010EP1	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION	14765105.3	3/14/2014	EP2968291	1/20/2016	
12024-010HK1	HK - (Hong Kong)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION	16110953.6	3/14/2014	1222792A	7/14/2017	1222792B
12024-010HK2	HK - (Hong Kong)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION	19119906.6	2/22/2019	1260112A	12/13/2019	
12024-010JP1	JP - (Japan)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION	2016-503092	3/14/2014	2016-503092	3/14/2014	6337083
12024-010JP2	JP - (Japan)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION	2018-089382	3/14/2014	2018-150333	9/27/2018	6517401
12024-010JP3	JP - (Japan)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION	2019-077828	4/16/2019			
12024-010MO1	MO - (Macao)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION	J/0003324	3/14/2014			J/0003324
12024-010P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	Pyrazinopyrrolyrimidines For Use As Anti-Neoplastic Agents	61/861.374	8/1/2013			
12024-010P2	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	Pyrazinopyrrolyrimidines For Use As Anti-Neoplastic Agents	61/911.354	12/3/2013			
12024-010P3	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation	61/949.786	3/7/2014			
12024-010US1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation	14/214.048	3/14/2014	US 2014-0271466 A1	9/18/2014	9,527,857
12024-010US2	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation	15/387.083	12/21/2016	US-2017-0100405-A1	4/13/2017	10076523
12024-010US3	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION	16/112.362	8/24/2018	US 2018-0360841 A1	12/20/2018	10434104
12024-010US4	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION	16/178.419	11/1/2018	US 2019-0070185 A1	3/7/2019	
12024-010WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION	PCT/US2014/029429	3/14/2014	WO/2014/144847	9/18/2014	
12024-011CA1	CA - (Canada)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS	2,906.157	3/14/2014			

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
		INC. - (GTI)							
12024-011CNIDIV	CN - (China P.R.)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS	201710147181.4	3/14/2014	CN 107417691 A	12/1/2017	
12024-011EP1	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS	14764016.3	3/14/2014	EP2967050	1/20/2016	
12024-011JP1	JP - (Japan)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS	2016-503044	3/14/2014	2016-518337	6/23/2016	6435315
12024-011JP2	JP - (Japan)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS	2018-202981	3/14/2014			
12024-011P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	Highly Active Anti-Neoplastic and Anti-Proliferative Agents	61/949,795	3/7/2014			
12024-011US4	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS	16/228,308	12/20/2018	US 2019-0125752 A1	5/2/2019	
12024-011WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS	PCT/US2014/029274	3/14/2014	WO/2014/144740	9/18/2014	
12024-012AU1	AU - (Australia)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	LACTAM KINASE INHIBITORS	2013239816	3/27/2013	2013239816	10/30/2014	2013239816
12024-012CA1	CA - (Canada)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	LACTAM KINASE INHIBITORS	2,868,966	3/27/2013	2,868,966	10/3/2013	
12024-012DE1	DE - (Germany)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	LACTAM KINASE INHIBITORS	13770192.6	3/27/2013	EP2831080	2/4/2015	60 2013 018 619.7
12024-012EP1	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	LACTAM KINASE INHIBITORS	13770192.6	3/27/2013	EP2831080	2/4/2015	EP2831080
12024-012EP2	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	LACTAM KINASE INHIBITORS	17155466.0	3/27/2013	3216792	9/13/2017	
12024-012GB1	GB - (Great Britain)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	LACTAM KINASE INHIBITORS	13770192.6	3/27/2013	EP2831080	2/4/2015	EP2831080
12024-012HK1	HK - (Hong Kong)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	LACTAM KINASE INHIBITORS	18103455.2	3/27/2013	1244004	7/27/2018	

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-012P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Inactive - (I)	LACTAM KINASE INHIBITORS	61/617,657	3/29/2012			
12024-012US1	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	LACTAM KINASE INHIBITORS	14/498,796	3/27/2013	US 2015-0018348 A1	1/15/2015	9,260,442
12024-012US2	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	LACTAM KINASE INHIBITORS	14/982,443	12/29/2015	US-2016-0108054-A1	4/21/2016	9,745,316
12024-012US3	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	LACTAM KINASE INHIBITORS	15/348,862	11/10/2016	US-2017-0057972-A1	3/2/2017	9,856,268
12024-012US4	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	LACTAM KINASE INHIBITORS	15/860,483	1/22/2018	US 2018-0127431 A1	5/10/2018	10464940
12024-012WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTT)	Inactive - (I)	LACTAM KINASE INHIBITORS	PCT/US2013/033971	3/27/2013	WO/2013/148748	10/3/2013	
12024-015P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Inactive - (I)	Tricyclic Lactams for Use in HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation	61/980,918	4/17/2014			
12024-015US1	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	Tricyclic Lactams for Use in HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation	14/690,180	4/17/2015	US 2015-0299212 A1	10/22/2015	9,717,735
12024-015US2	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TRICYCLIC LACTAMS FOR USE IN HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION	15/665,071	7/31/2017	2017-0333440	11/23/2017	10376519
12024-015WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	TRICYCLIC LACTAMS FOR USE IN HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION	PCT/US2015/026518	4/17/2015	WO 2015/161283	10/22/2015	
12024-025P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Inactive - (I)	Treatment of RB-Negative Tumors Using Topoisomerase Inhibitors in Combination with Cyclin Dependent Kinase 4/6 Inhibitors	62/050,035	9/12/2014			
12024-025WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS	PCT/US2015/049756	9/11/2015	WO/2016/040848	3/17/2016	
12024-025WO1US2	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS	16/142,574	9/26/2018	US 2019-0030034 A1	1/31/2019	10413547
12024-025WO1US3	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS	16/572,418	9/16/2019	US 2020-0022983 A1	1/23/2020	

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
				CYCLIN DEPENDENT KINASE 4/6 INHIBITORS					
12024-026EP1	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS	15840655.3	9/11/2015	3191098	7/19/2017	
12024-026P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	Anti-Neoplastic Combinations and Dosing Regimens Using CDK4/6 Inhibitor Compounds to Treat RB-Positive Tumors	62/050,043	9/12/2014			
12024-026WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS	PCT/US2015/049777	9/11/2015	WO/2016/040858	3/17/2016	
12024-026WO1US1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	Anti-Neoplastic Combinations and Dosing Regimens using CDK4/6 Inhibitor Compounds to Treat RB-Positive Tumors	15/457,699	9/11/2015	US-2017-0182043-A1	6/29/2017	10,231,969
12024-026WO1US2	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	Anti-Neoplastic Combinations and Dosing Regimens using CDK4/6 Inhibitor Compounds to Treat RB-Positive Tumors	16/254,364	1/22/2019	US 2019-0151311 A1	5/23/2019	
12024-035AP1	AP - (A.R.L.P.O.)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	AP/P/2019/011285	6/29/2017			
12024-035AU1	AU - (Australia)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	2017290362	6/29/2017			
12024-035BR1	BR - (Brazil)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	BR 11 2018 077155 4	6/29/2017	BR 11 2018 077155 4 A2	4/2/2019	
12024-035CA1	CA - (Canada)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	3,028,752	6/29/2017			
12024-035CN1	CN - (China P.R.)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	201780041253.5	6/29/2017	CN 109789142 A	5/21/2019	
12024-035EA1	EA - (Eurasian Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	201990189	6/29/2017			
12024-035EP1	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	17821293.2	6/29/2017	3478295	5/8/2019	
12024-035HK1	HK - (Hong Kong)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	19131880.7	11/5/2019			
12024-035IL1	IL - (Israel)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	263911	6/29/2017			

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-035IN1	IN - (India)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	201917001253	6/29/2017	201917001253A	3/29/2019	
12024-035JP1	JP - (Japan)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	2018-569090	6/29/2017	2019-520380	7/18/2019	
12024-035KR1	KR - (Republic of Korea)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	10-2019-7002844	6/29/2017			
12024-035MX1	MX - (Mexico)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	MX/a/2019/000199	6/29/2017	MX/a/2019/000199	10/7/2019	
12024-035NZ1	NZ - (New Zealand)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	749275	6/29/2017			
12024-035P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	62/357,797	7/1/2016			
12024-035RU1	RU - (Russian Federation)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	2019102643	6/29/2017			
12024-035WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	PCT/US2017/040102	6/29/2017	WO 2018/005865	1/4/2018	
12024-035WO1US1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	16/230,381	6/29/2017	US 2019-0135820-A1	5/9/2019	
12024-035ZA1	ZA - (South Africa)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES	2018/08535	6/29/2017			
12024-037P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS	62/357,516	7/1/2016			
12024-037WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS	PCT/US2017/039556	6/27/2017	WO 2018/005533	1/4/2018	
12024-037WO1US1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS	16/230,388	6/27/2017	US 2019-0135784-A1	5/9/2019	
12024-038AP1	AP - (A.R.L.P.O.)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	AP/P/2019/011284	6/29/2017			
12024-038AU1	AU - (Australia)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	2017290748	6/29/2017			
12024-038BR1	BR - (Brazil)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	BR 11 2018 077136 8	6/29/2017			

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-038CA1	CA - (Canada)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	3,028,751	6/29/2017			
12024-038CN1	CN - (China P.R.)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	201780041481.2	6/29/2017	CN 109789143 A	5/21/2019	
12024-038EA1	EA - (Eurasian Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	201990187	6/29/2017			
12024-038EP1	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	17821288.2	6/29/2017	3478294	5/8/2019	
12024-038HK1	HK - (Hong Kong)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	19131878.1	11/5/2019			
12024-038IL1	IL - (Israel)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	263910	6/29/2017	263910	1/31/2019	
12024-038IN1	IN - (India)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	201917000921	6/29/2017	201917000921A	3/22/2019	
12024-038JP1	JP - (Japan)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	2018-569079	6/29/2017	2019-520379	7/18/2019	
12024-038KR1	KR - (Republic of Korea)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	10-2019-7002845	6/29/2017			
12024-038MX1	MX - (Mexico)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	MX/a/2019/000200	6/29/2017	MX/a/2019/000200	10/7/2019	
12024-038NZ1	NZ - (New Zealand)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	749590	6/29/2017			
12024-038P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	62357,630	7/1/2016			
12024-038RU1	RU - (Russian Federation)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	2019102647	6/29/2017			
12024-038WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	PCT/US2017/040093	6/29/2017	WO 2018/005860	1/4/2018	
12024-038WO1US1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	16/230,396	6/29/2017	US 2019-0135811-A1	5/9/2019	

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-038ZAI	ZA - (South Africa)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS	2018/08536	6/29/2017			
12024-039PI	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER	62/357,818	7/1/2016			
12024-039WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER	PCT/US2017/040097	6/29/2017	WO 2018/005863	1/4/2018	
12024-039WO1US1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Granted - (G)	PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER	16/230,412	6/29/2017	US 2019-0119294 A1	4/25/2019	10618905
12024-039WO1US2	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER	16/847,426	4/13/2020			
12024-043AP1	AP - (A.R.L.P.O.)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	AP/P/2019/012102	6/29/2018			
12024-043AU1	AU - (Australia)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	2018291026	6/29/2018			
12024-043BR1	BR - (Brazil)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	BR 11 2019 027967 9	6/29/2018			
12024-043CA1	CA - (Canada)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	3,067,873	6/29/2018			
12024-043CN1	CN - (China P.R.)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	20188004381.5.4	6/29/2018	CN 110913861 A	3/24/2020	
12024-043EAI	EA - (Eurasian Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	201992768	6/29/2018			
12024-043EP1	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	18825503.8	6/29/2018			
12024-043IL1	IL - (Israel)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	271543	6/29/2018			
12024-043IN1	IN - (India)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	201917052187	6/29/2018			
12024-043JP1	JP - (Japan)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	2019-571988	6/29/2018			

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-043KR1	KR - (Republic of Korea)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	10-2020-7002180	6/29/2018			
12024-043MX1	MX - (Mexico)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	MX/a/2019/015384	6/29/2018			
12024-043NZ1	NZ - (New Zealand)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	759691	6/29/2018			
12024-043P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	62/526,937	6/29/2017			
12024-043RU1	RU - (Russian Federation)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	2019142591	6/29/2018			
12024-043WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	PCT/US18/40435	6/29/2018	WO 2019/006393	1/3/2019	
12024-043WO1US1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	16/721,631	6/29/2018			
12024-043ZA1	ZA - (South Africa)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF	2019/07981	6/29/2018			
12024-044AP1	AP - (A.R.L.P.O.)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	AP/P/2018/010830	12/9/2016			
12024-044AU1	AU - (Australia)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	2016366680	12/9/2016			
12024-044BR1	BR - (Brazil)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	BR 11 2018 011607 6	12/9/2016			
12024-044CA1	CA - (Canada)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	3,008,020	12/9/2016			
12024-044CN1	CN - (China P.R.)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	201680071852.7	12/9/2016	108495628	9/4/2018	
12024-044EA1	EA - (Eurasian Patent Convention)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	201891376	12/9/2016			

Patent Number	Country / Region	Current Office	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-044EP1	EP - (European Patent Convention)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	16874012.4	12/9/2016	3386500	10/17/2018	
12024-044HK1	HK - (Hong Kong)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	19122110.0	4/10/2019	1262188 A	1/10/2020	
12024-044IL1	IL - (Israel)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	259566	12/9/2016			
12024-044IN1	IN - (India)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	201817025208	12/9/2016			
12024-044JP1	JP - (Japan)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	2018-529925	12/9/2016	2019-502675	1/31/2019	
12024-044KR1	KR - (Republic of Korea)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	10-2018-7019088	12/9/2016			
12024-044MX1	MX - (Mexico)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	MX/A/2018/007079	12/9/2016	MX/A/2018/007079	12/18/2018	
12024-044NZ1	NZ - (New Zealand)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	743651	12/9/2016			
12024-044P1	US - (United States)	G1 THERAPEUTICS, INC. - (GT1)	Inactive - (I)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	62/264,971	12/9/2015			
12024-044P2	US - (United States)	G1 THERAPEUTICS, INC. - (GT1)	Inactive - (I)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	62/322,878	4/15/2016			
12024-044RU1	RU - (Russian Federation)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	2018125046	12/9/2016			
12024-044US1	US - (United States)	G1 THERAPEUTICS, INC. - (GT1)	Granted - (G)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	15/374,966	12/9/2016	US-2017-0166550-A1	6/15/2017	10118910
12024-044US2	US - (United States)	The Board of Trustees of the University of	Granted - (G)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	16/169,812	10/24/2018	US-2019-0055209-A1	2/21/2019	10377735

Patent Number	Country / Region	Current Office	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
		Illinois - (BOT)							
12024-044US3	US - (United States)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	16/537,079	8/9/2019	US 2020-0079752 A1	3/12/2020	
12024-044WO1	WO - (Patent Cooperation Treaty)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	PCT/US2016/066023	12/9/2016	WO 2017/100712	6/15/2017	
12024-044ZA1	ZA - (South Africa)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS	2018/03422	12/9/2016			
12024-045AP1	AP - (A.R.L.P.O.)	THE RAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	AP/P/2019/011617	12/5/2017			
12024-045AU1	AU - (Australia)	THE RAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	2017372856	12/5/2017			
12024-045BR1	BR - (Brazil)	THE RAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	BR112019011410-6	12/5/2017	BR 11 2019 011410 6 A2	6/25/2019	
12024-045CA1	CA - (Canada)	THE RAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	3,045,465	12/5/2017			
12024-045CN1	CN - (China P.R.)	THE RAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	201780075215.1	12/5/2017	CN 110035759 A	7/19/2019	
12024-045EA1	EA - (Eurasian Patent Convention)	THE RAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	201991313	12/5/2017			
12024-045EP1	EP - (European Patent Convention)	THE RAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	17878506.9	12/5/2017	3548030	10/9/2019	
12024-045HK1	HK - (Hong Kong)	THE RAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	62020001538.1	1/16/2020			
12024-045IL1	IL - (Israel)	THE RAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	266870	12/5/2017			
12024-045JP1	JP - (Japan)	THE RAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	2019-530011	12/5/2017			

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-045KR1	KR - (Republic of Korea)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	10-2019-7019110	12/5/2017			
12024-045MX1	MX - (Mexico)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	MX/a/2019/006523	12/5/2017	MX/a/2019/006523	11/11/2019	
12024-045NZ1	NZ - (New Zealand)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	753631	12/5/2017			
12024-045P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	ENHANCED PRIMING OF AN ANTI-CANCER IMMUNE RESPONSE USING HIGHLY SELECTIVE CDK4/6 INHIBITORS	62/430,302	12/5/2016			
12024-045P2	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	Enhanced Priming of an Anti-Cancer Immune Response using Highly Selective CDK4/6 Inhibitors	62/479,605	3/31/2017			
12024-045RU1	RU - (Russian Federation)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	2019120160	12/5/2017			
12024-045WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	PCT/US2017/064775	12/5/2017	WO 2018/106729	6/14/2018	
12024-045WO1US1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	16/432,244	12/5/2017	US 2019-0321370 A1	10/24/2019	
12024-045ZA1	ZA - (South Africa)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS	2019/03239	12/5/2017			
12024-046CN1	CN - (China P.R.)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS	201680071904.0	12/9/2016	CN 108699024 A	10/23/2018	
12024-046EP1	EP - (European Patent Convention)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS	16874015.7	12/9/2016	3386968	10/17/2018	
12024-046US2	US - (United States)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS	16/424,240	5/28/2019			
12024-046WO1	WO - (Patent Cooperation Treaty)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS	PCT/US2016/066026	12/9/2016	WO 2017/100715	6/15/2017	
12024-047P1	US - (United States)	The Board of Trustees of the University of Illinois - (BOT)	Inactive - (I)	NOVEL BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS & MIXED-FUNCTION DOWNREGULATORS	62/411,988	10/24/2016			

Patent Number	Country / Region	Current Office	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-047WO1	WO - (Patent Cooperation Treaty)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE MIXED ESTROGEN RECEPTOR DOWNREGULATORS	PCT/US2017/058145	10/24/2017	WO 2018/081168	5/3/2018	
12024-047WO1US1	US - (United States)	The Board of Trustees of the University of Illinois - (BOT)	Filed - (F)	BENZOTHIOPHENE-BASED SELECTIVE MIXED ESTROGEN RECEPTOR DOWNREGULATORS	16/393,258	10/24/2017	US 2019-0248780 A1	8/15/2019	
12024-048AP1	AP - (A.R.L.P.O.)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	AP/P/2019/011700	1/5/2018			
12024-048AR1	AR - (Argentina)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	20180100028	1/5/2018			
12024-048AU1	AU - (Australia)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	2018205262	1/5/2018			
12024-048BR1	BR - (Brazil)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	BR 11 2019 013814 5	1/5/2018			
12024-048CA1	CA - (Canada)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	3,048,057	1/5/2018			
12024-048CN1	CN - (China P.R.)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	201880006132.1	1/5/2018	CN 11017754 A	8/27/2019	
12024-048EA1	EA - (Eurasian Patent Convention)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	201991622	1/6/2017			
12024-048EP1	EP - (European Patent Convention)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	18736115.9	1/5/2018	3565558	11/13/2019	
12024-048HK1	HK - (Hong Kong)	G1 Therapeutics, Inc & The Board	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	62020003011.7	2/19/2020			

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
		of Trustees of the University of Illinois - (GTBT)							
12024-048IL1	IL - (Israel)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	267795	1/5/2018			
12024-048IN1	IN - (India)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	201917029566	1/5/2018	201917029566A	10/11/2019	
12024-048JP1	JP - (Japan)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	2019-536274	1/5/2018			
12024-048KR1	KR - (Republic of Korea)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	10-2019-7022662	1/5/2018	1020190103285	9/4/2019	
12024-048MX1	MX - (Mexico)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	MX/A/2019/008158	1/5/2018	MX/A/2019/008158	1/14/2020	
12024-048NZ1	NZ - (New Zealand)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	754865	1/5/2018			
12024-048P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	62/443,588	1/6/2017			
12024-048RU1	RU - (Russian Federation)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	2019124081	1/5/2018			
12024-048TW1	TW - (Taiwan)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	107100581	1/5/2018	201836600	10/16/2018	
12024-048WO1	WO - (Patent Cooperation Treaty)	G1 Therapeutics, Inc & The Board of Trustees of the University of	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	PCT/US2018/012675	1/5/2018	WO 2018/129387	7/12/2018	

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
		Illinois - (GTBT)							
12024-048WO1US1	US - (United States)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR TREATMENT OF CANCER	16/460,502	1/5/2018	US 2019-0321332 A1	10/24/2019	
12024-048ZA1	ZA - (South Africa)	G1 Therapeutics, Inc & The Board of Trustees of the University of Illinois - (GTBT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	2019/04188	1/5/2018			
12024-051CN1	CN - (China P.R.)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	TREATMENT OF EGFR-DRIVEN CANCER WITH FEWER SIDE EFFECTS	201880013231.2	2/22/2018	CN 110325191 A	10/11/2019	
12024-051EP1	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	TREATMENT OF EGFR-DRIVEN CANCER WITH FEWER SIDE EFFECTS	18758002.2	2/22/2018	3585389	1/1/2020	
12024-051PI	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Inactive - (I)	Reversing Acquired Resistance In EGFR-Mutated Non-Small Cell Lung Carcinoma	62/462,094	2/22/2017			
12024-051WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	TREATMENT OF EGFR-DRIVEN CANCER WITH FEWER SIDE EFFECTS	PCT/US18/19291	2/22/2018	WO 2018/156812	8/30/2018	
12024-051WO1US1	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	TREATMENT OF EGFR-DRIVEN CANCER WITH FEWER SIDE EFFECTS	16/547,342	2/22/2018	US 2019-0374545 A1	12/12/2019	
12024-052AR1	AR - (Argentina)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	20180100320	2/9/2018			
12024-052AU1	AU - (Australia)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS	2018217809	2/9/2018			
12024-052CA1	CA - (Canada)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS	3,052,810	2/9/2018			
12024-052CN1	CN - (China P.R.)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS	201880020916.X	2/9/2018	CN 110461853 A.	11/15/2019	
12024-052EP1	EP - (European Patent Convention)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS	18751944.2	2/9/2018	3580223	12/18/2019	
12024-052IL1	IL - (Israel)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS	268319	2/9/2018			

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-052IN1	IN - (India)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS	201917035319	2/9/2018	201917035319A	10/25/2019	
12024-052JP1	JP - (Japan)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS	2019-542672	2/9/2018			
12024-052KR1	KR - (Republic of Korea)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS	10-2019-7026068	2/9/2018			
12024-052P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Inactive - (I)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS	62/457,643	2/10/2017			
12024-052P2	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Inactive - (I)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS	62/460,358	2/17/2017			
12024-052P3	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Inactive - (I)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS	62/614,279	1/5/2018			
12024-052TW1	TW - (Taiwan)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	107104795	2/9/2018	201835064	10/1/2018	
12024-052US1	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS	15/893,295	2/9/2018	US 2018-0230123 A1	8/16/2018	10,208,011
12024-052US2	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS	16/221,201	12/14/2018	US 2019-0119243 A1	4/25/2019	10633362
12024-052US3	US - (United States)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS	16/824,290	3/19/2020			
12024-052WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS	PCT/US2018/017668	2/9/2018	WO 2018/148576	8/16/2018	
12024-054CA1	CA - (Canada)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	SYNTHESIS OF LACTAMIS	2,870,019	4/24/2013	2870019	10/31/2013	
12024-054IL1	IL - (Israel)	G1 THERAPEUTICS, INC. - (GTT)	Granted - (G)	SYNTHESIS OF LACTAMIS	235209	4/24/2013		10/31/2018	235209
12024-054IL2	IL - (Israel)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	SYNTHESIS OF LACTAMIS	262055	4/24/2013	262055	11/29/2018	
12024-054IN1	IN - (India)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	SYNTHESIS OF LACTAMIS	2205/KOLNP/2014	4/24/2013	06/2015	2/6/2015	
12024-054MY1	MY - (Malaysia)	G1 THERAPEUTICS, INC. - (GTT)	Filed - (F)	SYNTHESIS OF LACTAMIS	PI 2014703105	4/24/2013			

Patent Number	Country / Region	Current Office	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-054US1	US - (United States)	ChemoGenics BioPharma, LLC - (CGB)	Granted - (G)	SYNTHESIS OF LACTAMIS	14/396,759	4/24/2013	2015-0087831 A1	3/26/2015	10,202,392
12024-054US2	US - (United States)	ChemoGenics BioPharma, LLC - (CGB)	Filed - (F)	SYNTHESIS OF LACTAMIS	16/227,456	12/20/2018	US 2019-0119293 A1	4/25/2019	
12024-054WO1	WO - (Patent Cooperation Treaty)	ChemoGenics BioPharma, LLC - (CGB)	Inactive - (I)	SYNTHESIS OF LACTAMIS	PCT/US2013/037878	4/24/2013	WO2013/163239	10/31/2013	
12024-057P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	Pyrimidine-Based Compounds for the Treatment of Neoplastic Disorders	62/613,727	1/4/2018			
12024-057WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION	PCT/US2019/012343	1/4/2019	WO 2019/136244	7/11/2019	
12024-058P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	G1T38 SUPERIOR DOSAGE REGIMES	62/614,952	1/8/2018			
12024-058P2	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	G1T38 SUPERIOR DOSAGE REGIMES	62/679,575	6/1/2018			
12024-058P3	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	G1T38 SUPERIOR DOSAGE REGIMES	62/788,017	1/3/2019			
12024-058WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	G1T38 SUPERIOR DOSAGE REGIMES	PCT/US19/12720	1/8/2019	WO 2019/136451	7/11/2019	
12024-060P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	TREATMENT OF CANCERS HAVING DRIVING ONCOGENIC MUTATIONS USING SELECTIVE COMBINATION THERAPIES	62/655,135	4/9/2018			
12024-060P2	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	TREATMENT OF CANCERS HAVING DRIVING ONCOGENIC MUTATIONS USING SELECTIVE COMBINATION THERAPIES	62/657,373	4/13/2018			
12024-060P3	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	TREATMENT OF CANCERS HAVING DRIVING ONCOGENIC MUTATIONS USING SELECTIVE COMBINATION THERAPIES	62/788,024	1/3/2019			
12024-060P4	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	TREATMENT OF CANCERS HAVING DRIVING ONCOGENIC MUTATIONS USING SELECTIVE COMBINATION THERAPIES	62/810,802	2/26/2019			
12024-060WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	TREATMENT OF CANCERS HAVING DRIVING ONCOGENIC MUTATIONS USING SELECTIVE COMBINATION THERAPIES	PCT/US19/26656	4/9/2019	WO/2019/199883	10/17/2019	
12024-061P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Inactive - (I)	CDK INHIBITORS FOR THE TREATMENT OF NEOPLASTIC	62/672,474	5/16/2018			

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
		INC. - (GTI)		DISORDERS					
12024-061P2	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	CDK INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISORDERS	62/827,696	4/1/2019			
12024-061WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	CDK INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISORDERS	PCT/US19/32698	5/16/2019	WO/2019/222521	11/21/2019	
12024-062P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE	62/722,675	8/24/2018			
12024-062WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	IMPROVED SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE	PCT/US19/48029	8/23/2019	WO/2020/041770	2/27/2020	
12024-064P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS	62/764,757	8/16/2018			
12024-064WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS	PCT/US2019/046892	8/16/2019	WO/2020/037251	2/20/2020	
12024-065P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	CELL CYCLE INHIBITING COMPOUNDS FOR THE TREATMENT OF NEOPLASTIC DISORDERS	62/827,703	4/1/2019			
12024-065P2	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	CELL CYCLE INHIBITING COMPOUNDS FOR THE TREATMENT OF NEOPLASTIC DISORDERS	62/870,351	7/3/2019			
12024-065WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	CELL CYCLE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS	PCT/US20/26262	4/1/2020			
12024-066P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	ERIBULIN AND SELECTIVE CDK4/6 INHIBITOR COMBINATIONS	62/758,388	11/9/2018			
12024-066WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	THERAPEUTIC REGIMENS FOR TREATMENT OF CANCER USING ERIBULIN AND SELECTIVE CDK4/6 INHIBITOR COMBINATIONS	PCT/US19/61010	11/12/2019			
12024-068P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS	62/827,692	4/1/2019			
12024-068P2	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS	62/870,357	7/3/2019			
12024-068WO1	WO - (Patent Cooperation Treaty)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS	PCT/US20/26263	4/1/2020			
12024-069P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	SURVIVAL IN TRIPLE NEGATIVE BREAST CANCER	62/863,153	6/18/2019			

Patent Number	Country / Region	Current Owner	Status	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number
12024-069P2	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	MEANS FOR ENHANCEMENT OF ANTI-TUMOR IMMUNITY IN CANCER PATIENTS	62/907,375	9/27/2019			
12024-072P1	US - (United States)	G1 THERAPEUTICS, INC. - (GTI)	Filed - (F)	TARGETED TREATMENT OF CANCERS WITH MUTATIONS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR	62/913,055	10/9/2019			
12024-004U51	US - (United States)	G1 THERAPEUTICS, INC - (GTI); U. of NORTH CAROLINA; BRIGHAM & WOMEN'S HOSPITAL	Granted - (G)	PROTECTION OF RENAL TISSUES FROM ISCHEMIA THROUGH INHIBITION OF THE PROLIFERATION OF THE PROLIFERATIVE KINASES CDK4 AND CDK6	13/988,158	11/17/2011	US 201,303,03543	11/14/2013	9808461

EXHIBIT C

Trademarks

None.

EXHIBIT D

Mask Works

None.

US-DOCS\116069777.2